14,068 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Purchased by Torray Investment Partners LLC

Torray Investment Partners LLC acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 14,068 shares of the pharmaceutical company's stock, valued at approximately $5,724,000.

Several other large investors have also made changes to their positions in VRTX. OFI Invest Asset Management bought a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $25,000. Arlington Trust Co LLC lifted its holdings in shares of Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 33 shares during the period. Fortitude Family Office LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $30,000. Baystate Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company's stock valued at $31,000 after acquiring an additional 25 shares in the last quarter. Finally, NBC Securities Inc. purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $34,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the firm's stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock traded down $1.34 during trading hours on Tuesday, hitting $428.59. The company had a trading volume of 935,882 shares, compared to its average volume of 1,220,610. The firm has a market cap of $110.60 billion, a PE ratio of 27.76, a PEG ratio of 2.06 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. Vertex Pharmaceuticals Incorporated has a one year low of $320.01 and a one year high of $448.40. The firm has a 50-day moving average of $407.74 and a 200 day moving average of $402.36.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.66 by $1.10. The business had revenue of $2.69 billion for the quarter, compared to analysts' expectations of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The firm's quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the firm posted $2.67 earnings per share. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 14.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VRTX has been the topic of a number of recent research reports. William Blair reissued an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 6th. Truist Financial raised their price target on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a "buy" rating in a research note on Wednesday, January 31st. Canaccord Genuity Group reiterated a "sell" rating and issued a $371.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, April 12th. Piper Sandler lifted their target price on shares of Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an "overweight" rating in a research note on Tuesday, May 7th. Finally, UBS Group dropped their price objective on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a "buy" rating for the company in a research report on Wednesday, April 17th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $432.18.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.